One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

The novel long-acting β (2)-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:COPD
Main Authors: McGarvey, Lorcan, Niewoehner, Dennis, Magder, Sheldon, Sachs, Paul, Tetzlaff, Kay, Hamilton, Alan, Korducki, Lawrence, Bothner, Ulrich, Vogelmeier, Claus, Koch, Andrea, Ferguson, Gary T.
Formato: Artigo
Idioma:Inglês
Publicado em: Informa Healthcare 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778540/
https://ncbi.nlm.nih.gov/pubmed/25692310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/15412555.2014.991864
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados